Stay updated with breaking news from Ilan Hadar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today
Tel Aviv, Israel - April 9, 2024 - PainReform Ltd. , a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced groundbreaking...
PainReform hits a 50% enrollment target in the Phase 3 trial for PRF-110 in bunionectomy. No serious adverse events were reported. Over 200 patients enrolled across 8 U.S. sites. CEO Ilan Hadar is optimistic about PRF-110's potential to revolutionize postoperative pain management.
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ('PainReform' or the 'Company'), a clinical-stage specialty p...
TEL AVIV, Israel, Dec. 26, 2023 -- PainReform Ltd. , a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into a...